Failure of primary atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients.

Autor: Gajurel K; Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, California, USA., Gomez CA; Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, California, USA., Dhakal R; Toxoplasma Serology Laboratory, National Reference Center for the Study and Diagnosis of Toxoplasmosis, Palo Alto, California, USA., Vogel H; Department of Pathology, School of Medicine, Stanford University, Stanford, California, USA., Montoya JG; Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, California, USA.; Toxoplasma Serology Laboratory, National Reference Center for the Study and Diagnosis of Toxoplasmosis, Palo Alto, California, USA.
Jazyk: angličtina
Zdroj: Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2016 Jun; Vol. 18 (3), pp. 446-452. Date of Electronic Publication: 2016 Jun 09.
DOI: 10.1111/tid.12532
Abstrakt: The efficacy of primary prophylaxis with atovaquone in preventing Toxoplasma reactivation and disease in hematopoietic cell transplant (HCT) recipients is unknown. We describe 2 cases of atovaquone prophylaxis failure in pre-HCT Toxoplasma-seropositive (pre-HCTSP) recipients who underwent allogeneic HCT (allo-HCT) and review the literature on atovaquone prophylaxis in HCT recipients.
(© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje